EMBL Ventures
19
18M
13
0.95
4
0.32
6
- Stages of investment
- Areas of investment
Summary
The leading representative office of defined VC is situated in the Heidelberg. The venture was found in Europe in Germany.
Speaking about the real fund results, this VC is 11 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this EMBL Ventures performs on 4 percentage points less the average number of lead investments. The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2013. The increased amount of exits for fund were in 2017. Deals in the range of 10 - 50 millions dollars are the general things for fund.
We also calculated 5 valuable employees in our database.
Among the most popular fund investment industries, there are Biopharma, Medical. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the location of its establishment and the land of its numerous investments - Germany. Among the most popular portfolio startups of the fund, we may highlight Vasopharm, Opsona, Crescendo Biologics.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the EMBL Ventures, startups are often financed by Sofinnova Partners, Seroba Life Sciences, Inventages Venture Capital Investment Inc.. The meaningful sponsors for the fund in investment in the same round are Andera Partners, Wellington Partners, Sunstone Life Science Ventures. In the next rounds fund is usually obtained by Wellington Partners, dievini Hopp Biotech Holding, Entrepreneurs Fund.
Investments analytics
Analytics
- Total investments
- 19
- Lead investments
- 4
- Exits
- 6
- Rounds per year
- 0.95
- Follow on index
- 0.32
- Investments by industry
- Biotechnology (18)
- Health Care (9)
- Therapeutics (7)
- Medical (7)
- Pharmaceutical (4) Show 9 more
- Investments by region
-
- Germany (12)
- United Kingdom (2)
- Austria (2)
- Ireland (2)
- Romania (1)
- Peak activity year
- 2013
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Avg. valuation at time of investment
- 18M
- Group Appearance index
- 0.95
- Avg. company exit year
- 6
- Avg. multiplicator
- 5.62
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Allecra Therapeutics | 18 Apr 2013 | Biotechnology, Pharmaceutical, Biopharma | Early Stage Venture | 17M | Germany, Baden-Württemberg |
| Opsona | 29 Apr 2013 | Biotechnology, Health Care, Medical, Therapeutics | Late Stage Venture | 38M | County Dublin, Dublin, Ireland |
| SharpestMinds | 04 Jan 2018 | Recruiting, Artificial Intelligence, Machine Learning, Education | Seed | 120K | Ontario, Old Toronto, Canada |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.